Michael Houghton
Overview
Explore the profile of Michael Houghton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
2745
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bai B, Srinivas Kandadai A, Hena M, Belovodskiy A, Shen J, Houghton M, et al.
ChemMedChem
. 2024 Dec;
:e202400629.
PMID: 39656778
The development of non-nucleoside inhibitors targeting human cytomegalovirus (HCMV) polymerase presents a promising approach for enhancing therapeutic treatment for patients with sustained HCMV viremia. A series of non-nucleoside HCMV DNA...
2.
Meier-Stephenson V, Hawkes M, Burton C, Calcutt A, Davis C, Dooley J, et al.
Trials
. 2024 Nov;
25(1):781.
PMID: 39563457
Background: Group A streptococci (Strep A) orStreptococcus pyogenes is a major human pathogen causing an estimated 500,000 deaths worldwide each year. Disease can range from mild pharyngitis to more severe...
3.
Chen J, Lynn E, Sharma H, Byun J, Kenyon V, Sahu K, et al.
J Thromb Haemost
. 2024 Aug;
22(11):3290-3304.
PMID: 39111636
Background: The 78-kDa glucose-regulated protein (GRP78) expressed on the cell surface (csGRP78) has been reported to regulate tissue factor (TF) procoagulant activity (PCA) in lesion-resident endothelial cells (ECs), which is...
4.
Kundu J, Le H, Logan M, Hockman D, Landi A, Crawford K, et al.
J Hepatol
. 2024 Jul;
81(6):941-948.
PMID: 38986744
Background & Aims: An optimal HCV vaccine requires the induction of antibodies that neutralise the infectivity of many heterogenous viral isolates. In this study, we have focused on determining the...
5.
Liang T, Law J, Pietschmann T, Ray S, Bukh J, Bull R, et al.
Clin Infect Dis
. 2023 Aug;
77(Suppl 3):S257-S261.
PMID: 37579208
For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of...
6.
Shen Q, Hossain F, Fang C, Shu T, Zhang X, Law J, et al.
ACS Appl Mater Interfaces
. 2023 Jun;
15(25):29914-29926.
PMID: 37314985
An approach to assess severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (and past infection) was developed. For virus detection, the SARS-CoV-2 virus nucleocapsid protein (NP) was targeted. To detect...
7.
Hossain F, Shen Q, Balasuriya N, Law J, Logan M, Houghton M, et al.
Anal Chem
. 2023 May;
95(19):7620-7629.
PMID: 37150898
A sensor capable of quantifying both anti-SARS-CoV-2 spike receptor-binding domain (RBD) antibody levels and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in saliva and serum was developed. This...
8.
9.
Kanai T, Hu Z, Yang R, Wu W, Wang Z, Ma C, et al.
J Virol
. 2022 Dec;
97(1):e0178822.
PMID: 36519897
Despite the development of highly effective hepatitis C virus (HCV) treatments, an effective prophylactic vaccine is still lacking. HCV infection is mediated by its envelope glycoproteins, E1 and E2, during...
10.
Zietara F, Crotty P, Houghton M, Tyrrell L, Coffin C, Macphail G
Can Liver J
. 2022 Aug;
3(3):276-285.
PMID: 35992530
Background: Approximately 60% of incident hepatitis C virus (HCV) infections are due to intravenous drug use; therefore, understanding the socio-demographics of people who inject drugs (PWID) is necessary to achieve...